Procaps Group SA
NASDAQ:PROC
Procaps Group SA
Total Equity
Procaps Group SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Procaps Group SA
NASDAQ:PROC
|
Total Equity
-$900k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Procaps Group SA
Glance View
Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
See Also
What is Procaps Group SA's Total Equity?
Total Equity
-900k
USD
Based on the financial report for Dec 31, 2022, Procaps Group SA's Total Equity amounts to -900k USD.
What is Procaps Group SA's Total Equity growth rate?
Total Equity CAGR 1Y
98%
Over the last year, the Total Equity growth was 98%.
